Recurrent Diffuse Large B-Cell Lymphoma Clinical Trials in New York, New York
4 studies are recruiting for recurrent diffuse large b-cell lymphoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
- Locations
- 9 in total
- Run by
- National Cancer Institute (NCI)
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center, New York, New York
- Locations
- 7 in total
- Run by
- AIDS Malignancy Consortium
-
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
- Locations
- 87 in total
- Run by
- SWOG Cancer Research Network
-
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetosta…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
- Locations
- 104 in total
- Run by
- SWOG Cancer Research Network
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.